Kenji Mitsugi

4.2k total citations
59 papers, 664 citations indexed

About

Kenji Mitsugi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Kenji Mitsugi has authored 59 papers receiving a total of 664 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 11 papers in Molecular Biology. Recurrent topics in Kenji Mitsugi's work include Cancer Treatment and Pharmacology (18 papers), Colorectal Cancer Treatments and Studies (17 papers) and Gastric Cancer Management and Outcomes (12 papers). Kenji Mitsugi is often cited by papers focused on Cancer Treatment and Pharmacology (18 papers), Colorectal Cancer Treatments and Studies (17 papers) and Gastric Cancer Management and Outcomes (12 papers). Kenji Mitsugi collaborates with scholars based in Japan, United States and Greece. Kenji Mitsugi's co-authors include Hiroshi Ariyama, Eishi Baba, Shuji Nakano, Risa Tanaka, Taito Esaki, Hitoshi Kusaba, Koichi Akashi, Mine Harada, Yoshiyuki Niho and Yoshihiro Shibata and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Kenji Mitsugi

56 papers receiving 662 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kenji Mitsugi Japan 15 432 191 165 112 76 59 664
Hoo G. Chun United States 15 440 1.0× 210 1.1× 304 1.8× 154 1.4× 67 0.9× 31 821
Kian Fong Foo Singapore 13 320 0.7× 238 1.2× 141 0.9× 193 1.7× 66 0.9× 24 712
Moon Soo Lee South Korea 15 313 0.7× 198 1.0× 259 1.6× 133 1.2× 96 1.3× 58 692
Rossana Casaretti Italy 15 526 1.2× 209 1.1× 102 0.6× 105 0.9× 55 0.7× 44 657
D. P. Ryan United States 13 241 0.6× 180 0.9× 94 0.6× 108 1.0× 40 0.5× 31 510
Domenico Ciliberto Italy 14 415 1.0× 130 0.7× 219 1.3× 76 0.7× 68 0.9× 30 672
Massimo Zeuli Italy 14 546 1.3× 276 1.4× 226 1.4× 159 1.4× 90 1.2× 37 917
Aline Charabaty United States 12 358 0.8× 170 0.9× 78 0.5× 123 1.1× 34 0.4× 27 575
Guido Ceci Italy 15 455 1.1× 199 1.0× 215 1.3× 71 0.6× 67 0.9× 34 756

Countries citing papers authored by Kenji Mitsugi

Since Specialization
Citations

This map shows the geographic impact of Kenji Mitsugi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenji Mitsugi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenji Mitsugi more than expected).

Fields of papers citing papers by Kenji Mitsugi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenji Mitsugi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenji Mitsugi. The network helps show where Kenji Mitsugi may publish in the future.

Co-authorship network of co-authors of Kenji Mitsugi

This figure shows the co-authorship network connecting the top 25 collaborators of Kenji Mitsugi. A scholar is included among the top collaborators of Kenji Mitsugi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenji Mitsugi. Kenji Mitsugi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Komori, Azusa, Satoshi Otsu, Mototsugu Shimokawa, et al.. (2023). Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study. International Journal of Clinical Oncology. 28(8). 1073–1081. 1 indexed citations
2.
Shirakawa, Tsuyoshi, Mototsugu Shimokawa, Taiga Otsuka, et al.. (2023). MO61-6 Efficacy of third-line chemotherapy after liposomal irinotecan and fluorouracil with folinic acid for pancreatic cancer. Annals of Oncology. 34. S1435–S1435.
3.
Nishikawa, Kazuo, Shuichi Hironaka, Takashi Inagaki, et al.. (2022). A multicentre retrospective study comparing site-specific treatment with empiric treatment for unfavourable subset of cancer of unknown primary site. Japanese Journal of Clinical Oncology. 52(12). 1416–1422. 2 indexed citations
4.
5.
Ohmura, Hirofumi, Toshihiro Yamaguchi, Mamoru Ito, et al.. (2020). OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody. British Journal of Cancer. 122(10). 1507–1517. 51 indexed citations
6.
7.
Otsuka, Taiga, Mototsugu Shimokawa, Satoshi Otsu, et al.. (2019). A multicenter retrospective study of gemcitabine plus nab-paclitaxel or FOLFIRINOX in metastatic pancreatic cancer: NAPOLEON study. Annals of Oncology. 30. iv17–iv18. 5 indexed citations
8.
Yamaguchi, Toshihiro, Hitoshi Kusaba, Akitaka Makiyama, et al.. (2018). The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer. Cancer Chemotherapy and Pharmacology. 82(4). 625–633. 12 indexed citations
9.
10.
Kusaba, Hitoshi, Kenji Mitsugi, Akitaka Makiyama, et al.. (2017). Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. Cancer Chemotherapy and Pharmacology. 80(2). 333–342. 16 indexed citations
11.
Nio, Kenta, Shuji Arita, Taichi Isobe, et al.. (2015). Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy. Cancer Chemotherapy and Pharmacology. 75(4). 829–835. 14 indexed citations
12.
Kusaba, Hitoshi, Taito Esaki, Junji Kishimoto, et al.. (2012). Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer. Cancer Chemotherapy and Pharmacology. 71(1). 29–34. 1 indexed citations
13.
Baba, Eishi, Taito Esaki, Hiroshi Ariyama, et al.. (2010). Phase II study of sequential treatment with S-1 and cisplatin for metastatic gastric cancer. Cancer Chemotherapy and Pharmacology. 68(3). 611–617. 1 indexed citations
14.
Shibata, Yoshihiro, Eishi Baba, Hiroshi Ariyama, et al.. (2010). Irinotecan-based combination chemotherapy for metastatic small intestinal adenocarcinoma. Oncology Letters. 1(3). 423–426. 1 indexed citations
15.
Shibata, Yoshihiro, Hiroshi Ariyama, Eishi Baba, et al.. (2009). Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan. International Journal of Clinical Oncology. 14(5). 397–401. 31 indexed citations
16.
Kusaba, Hitoshi, Yoshihiro Shibata, Shuji Arita, et al.. (2007). Infusional 5-fluorouracil and cisplatin as first-line chemotherapy in patients with carcinoma of unknown primary site. Medical Oncology. 24(2). 259–264. 2 indexed citations
17.
Kato, Ken, Kenji Mitsugi, Minoru Nakamura, et al.. (2005). Feasibility study of ambulatory continuous infusion of 5-fluorouracil followed by cisplatin through hepatic artery for metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology. 57(1). 114–119. 3 indexed citations
18.
Tanaka, Risa, Yasushi Takii, Yoshihiro Shibata, et al.. (2005). In vitro sequence-dependent interaction between nedaplatin and paclitaxel in human cancer cell lines. Cancer Chemotherapy and Pharmacology. 56(3). 279–285. 9 indexed citations
19.
Ariyama, Hiroshi, Eishi Baba, Risa Tanaka, et al.. (2005). Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells. Journal of Cellular Biochemistry. 97(4). 724–734. 59 indexed citations
20.
Roy, Krishnendu, Kenji Mitsugi, & Francis M. Sirotnak. (1996). Organization and Alternate Splicing of the Murine Folylpolyglutamate Synthetase Gene. Journal of Biological Chemistry. 271(39). 23820–23827. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hoo G. Chun Breakdown of academic impact, for papers by Kian Fong Foo Breakdown of academic impact, for papers by Moon Soo Lee Breakdown of academic impact, for papers by Rossana Casaretti Breakdown of academic impact, for papers by D. P. Ryan Breakdown of academic impact, for papers by Domenico Ciliberto Breakdown of academic impact, for papers by Massimo Zeuli Breakdown of academic impact, for papers by Aline Charabaty Breakdown of academic impact, for papers by Guido Ceci
Rankless by CCL
2026